Market Overview

UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'

Related TKMR
Ebola Vaccine Contenders
Doctor Who Treated Ebola Patients in West Africa, Tests Positive for Ebola in New York City
Making Money With Charles Payne: 10/24/14 (Fox Business)

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares are trading seven percent higher Monday after Leerink revealed a $25 price target and Outperform rating.

The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”

TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.

Related Link: Deutsche Bank Raises Achillion Price Target 138%

Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.

The issue was last trading hands at $19.30, a 6.75 percent gain.

Latest Ratings for TKMR

DateFirmActionFromTo
Oct 2014Leerink SwannDowngradesOutperformMarket Perform
Aug 2014Leerink PartnersInitiates Coverage onOutperform
Jul 2014ClarusInitiates Coverage onBuy

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

Posted-In: Ebola Leerink Michael SchmidtAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (TKMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters